79
Active Trials
33
Phase 1
39
Phase 2
24
Phase 3
7
Therapeutic Areas
Portfolio Concentration: 76% of active trials in Oncology
Oncology
60 active / 95 total
Solid Tumor (Advanced)
12 active
24 total since 2015
NSCLC
10 active
5 Ph3
13 total since 2015
Hepatocellular Carcinoma
6 active
2 Ph3
11 total since 2015
Pancreatic Cancer
4 active
1 Ph3
4 total since 2015
Colorectal Cancer
4 active
1 Ph3
4 total since 2015
Lung Cancer (General)
2 active
1 Ph3
6 total since 2015
Cervical Cancer
2 active
2 Ph3
5 total since 2015
SCLC
2 active
1 Ph3
4 total since 2015
Gastric Cancer
2 active
4 total since 2015
Ovarian Cancer
2 active
3 total since 2015
Hodgkin Lymphoma
2 active
1 Ph3
3 total since 2015
Triple Negative Breast Cancer
2 active
1 Ph3
2 total since 2015
Cholangiocarcinoma
2 active
1 Ph3
2 total since 2015
Head and Neck Cancer
2 active
1 Ph3
2 total since 2015
AML
2 active
2 total since 2015
MDS
2 active
2 total since 2015
Esophageal Cancer
1 active
1 total since 2015
Renal Cell Carcinoma
1 active
1 total since 2015
Non-Hodgkin Lymphoma
0 active
1 total since 2015
Melanoma
0 active
1 total since 2015
Immunology
10 active / 32 total
Urology
4 active / 6 total
Respiratory
2 active / 3 total
CNS
1 active / 1 total
Metabolic
0 active / 7 total
Cardiovascular
0 active / 1 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)